Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
We've covered a wide range of topics in our "ASCO 2012 Lung Cancer Highlights" podcast series over the last few weeks. This webinar and the podcasts from it featured Drs. Mark Socinski from the University of Pittsburgh and Joel Neal from Stanford Cancer Center; following their presentations, they did a question and answer session together, covering a wide range of leading topics in lung cancer from ASCO. Here's that Q&A session.
ASCO 2012 LC Highlights QA Session Audio Podcast
ASCO 2012 LC Highlights QA Session Transcript
ASCO 2012 LC Highlights QA Session Figs
That's the end of this series, and we again thank LUNGevity Foundation for partnering with us to make it possible. I hope you found it valuable. If there was a favorite topic, or one that didn't get a mention that you hoped would, please let us know with a comment.
Please feel free to offer comments and raise questions in our
discussion forums.
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.